title: Imaging response in malignant glioma, RTOG 90-06.
abstract: OBJECTIVE
  The purpose of this study was to determine if radiographic response correlates with survival for patients treated patients with malignant gliomas treated on Radiation Therapy Oncology Group (RTOG) protocol 90-06. This study compared patients treated with hyperfractionated radiation and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) to standard fractionation and BCNU.
  
  
  METHODS
  There were 453 patients evaluable. Histology included anaplastic astrocytoma (60) (AA), and glioblastoma multiforme (312) (GBM). All scans were forwarded to the RTOG central office and evaluated by a single reviewer without knowledge of outcome. Response at 4 months post initiation of therapy was evaluated by computed tomography or magnetic resonance image and compared with overall survival.
  
  
  RESULTS
  For patients with no tumor on the 4 month scan the median survival was 20.3 months and the 2 year survival 43%. Patients with partial or minor response had a median survival of 18.1 and 14.2 months and 2 year survival of 37% and 29%. Patients with progression had a median survival of 8.6 months and 2 year survival of 10%.
  
  
  CONCLUSIONS
  Response rates were similar in both arms.
authors.affiliation: Hospital of the University of Pennsylvania, Department of Radiation Oncology, Philadelphia, PA 19104, USA. lustig@xrt.upenn.edu
authors.forename: Robert A
authors.initials: RA
authors.lastname: Lustig
authors.forename: Wendy
authors.initials: W
authors.lastname: Seiferheld
authors.forename: Brian
authors.initials: B
authors.lastname: Berkey
authors.forename: Alfred W K
authors.initials: AW
authors.lastname: Yung
authors.forename: Charles
authors.initials: C
authors.lastname: Scarantino
authors.forename: Benjamin
authors.initials: B
authors.lastname: Movsas
authors.forename: Christopher U
authors.initials: CU
authors.lastname: Jones
authors.forename: Joseph R
authors.initials: JR
authors.lastname: Simpson
authors.forename: Jennifer
authors.initials: J
authors.lastname: Fishbach
authors.forename: Walter J
authors.initials: WJ
authors.lastname: Curran
mesh_terms: D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use; D001254:Astrocytoma / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy; D001706:Biopsy; D001932:Brain Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy; D002330:Carmustine / Q000008:administration & dosage / Q000627:therapeutic use; D018450:Disease Progression; D005260:Female; D005909:Glioblastoma / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy; D005910:Glioma / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000401:mortality / Q000473:pathology* / Q000532:radiotherapy; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D016019:Survival Analysis; D014057:Tomography, X-Ray Computed
chemical_list: D018906:Antineoplastic Agents, Alkylating; D002330:Carmustine